Drug therapies in severe asthma-the era of stratified medicine

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 15, Issue 5, 2015, Pages 452-456

  Hetherington, Kathy J ^a   Heaney, Liam G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Personalised medicine; Severe asthma; Stratified medicine

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MEPOLIZUMAB; OMALIZUMAB; PREDNISONE;

ARTICLE; ASTHMA; BIOLOGICAL THERAPY; CATARACT; COMORBIDITY ASSESSMENT; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MEDICAL RESEARCH; MENTAL DISEASE; OSTEOPOROSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADULT; COMORBIDITY; PERSONALIZED MEDICINE;

ADRENAL CORTEX HORMONES; ADULT; ASTHMA; COMORBIDITY; HUMANS; PRECISION MEDICINE;

EID: 84943247633     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.15-5-452     Document Type: Article

References (36)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available online at www.ginasthma.org/local/uploads/files/GINA-Report-2014-Aug12.pdf [Accessed 19 March 2015].
2. Hekking P P, Wener RR, Amelink M et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015;135:896-902.
3. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005;365:974-6.
4. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73.
5. NHS England. A14/S/1b-2013/14 NHS standard contract for respiratory: severe asthma (adult). Available online at www.england. nhs.uk/wp-content/uploads/2013/06/a14-respiratory-sev-asthma. pdf [Accessed 19 March 2015].
6. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009;180:817-22.
7. Murphy AC, Proeschal A, Brightling CE et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 2012;67:751-3.
8. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24.
9. Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol 2015;135:822-4.
10. Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207.
11. McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012;186:1102-8.
12. Medical Research Council Refractory Asthma Stratification Programme in the United Kingdom (RASP-UK). Moving away from the 'one size fits all' approach to treatment in severe asthma. Available online at www.rasp.org.uk/[Accessed 19 March 2015].
13. Nieuwlaat R, Wilczynski N, Navarro T et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;11:1-730.
14. Leggett JJ, Johnston BT, Mills M et al. Prevalence of gastroesopha-geal reflux in difficult asthma: relationship to asthma outcome. Chest 2005;127:1227-31.
15. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003;2:1-33.
16. Rothenberg SS, Bratton D. The effects of laparoscopic Nissen fun-doplication to enhance pulmonary function in the treatment of a patient with severe asthma and gastroesophageal reflux disease. J Allergy Clin Immunol 2008;121:1069-70.
17. Sihvonen R, Paavola M, Malmivaara A et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med 2013;369:2515-24.
18. Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-23.
19. Gibson PG. Obesity and asthma. Ann Am Thorac Soc 2013;10 Suppl:S138-42.
20. Dias-Júnior SA, Reis M, de Carvalho-Pinto RM et al. Effects of weight loss on asthma control in obese patients with severe asthma. Eur Respir J 2014;43:1368-77.
21. Sweeney J, Brightling CE, Menzies-Gow AN et al. Regular oral corticosteroid use increases the risk of steroid related morbidity in refractory asthma compared to frequent rescue courses-data from the British Thoracic Society (BTS) Difficult Asthma Registry. Am J Respir Crit Care Med 2014;189:A2426.
22. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticos-teroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;2:1-17.
23. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000;2:1-57.
24. Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189-97.
25. Woodruff PG, Modreck B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95.
26. Jia G, Erickson RW, Choy DF et al. Periostin is a systemic bio-marker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-54.
27. Butler CA, McQuaid S, Taggart CC et al. Glucocorticoid receptor β and histone deacetylase 1 and 2 expression in the airways of severe asthma. Thorax 2012;67:392-8.
28. Shikotra A, Choy DF, Ohri CM et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol 2012;129:104-11.
29. Choy D, Shikotra A, Siddiqui S et al. Mutually exclusive Th2 and Th17 bronchial gene expression signatures are associated with eosinophilia in asthma. Eur Respir J 2014;44 Suppl 58;P3868.
30. McGrath KW, Icitovic N, Boushey HA et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185:612-19.
31. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353;2213-14.
32. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corti-costeroids for children and adults with asthma: a systematic review. Chest 2011;139:28-35.
33. Castro M, Rubin AS, Laviolette M et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a mul-ticenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181:116-24.
34. Busse WW, Holgate S, Kerwin E et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013;188:1294-302.
35. Brusselle GG, Joos G. Is there a role for macrolides in severe asthma? Curr Opin Pulm Med 2014;20:95-102.
36. Busse WW, Trzaskoma B, Omachi TA et al. Evaluating Xolair persistency of response after long-term therapy (XPORT). Am J Respir Crit Care Med 2014;189:A6576.